Last 7 days
-2.2%
Last 30 days
-5.6%
Last 90 days
-2%
Trailing 12 Months
-1.4%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
TMO | 218.4B | 44.9B | -5.62% | -1.44% | 31.38 | 4.86 | 14.55% | -9.94% |
ILMN | 35.5B | 4.6B | 5.65% | -27.02% | -8.07 | 7.75 | 1.28% | -677.95% |
MTD | 32.5B | 3.9B | -7.42% | 9.05% | 37.3 | 8.3 | 5.43% | 13.46% |
WAT | 18.2B | 3.0B | -10.97% | -4.88% | 25.66 | 6.11 | 6.68% | 2.15% |
BRKR | 10.8B | 2.5B | -3.73% | 16.11% | 36.41 | 4.27 | 4.67% | 7.04% |
MID-CAP | ||||||||
NEO | 2.4B | 509.7M | 46.19% | 25.15% | -16.73 | 4.74 | 5.24% | -1628.17% |
SMALL-CAP | ||||||||
PACB | 2.0B | 128.3M | -11.70% | -1.09% | -6.37 | 15.61 | -1.69% | -73.40% |
ADPT | 1.2B | 185.3M | -5.41% | -23.53% | -6 | 6.49 | 20.06% | 3.42% |
QTRX | 450.3M | 105.5M | -12.44% | -50.56% | -4.66 | 4.27 | -4.55% | -67.63% |
BNGO | 341.8M | 27.8M | -23.57% | -31.43% | -2.58 | 12.29 | 54.62% | -83.06% |
CDXS | 271.1M | 138.6M | -29.13% | -76.08% | -8.07 | 1.96 | 32.30% | -57.86% |
CDXC | 121.5M | 72.0M | -9.68% | -16.83% | -7.37 | 1.69 | 6.82% | 39.11% |
HBIO | 117.4M | 113.3M | -15.92% | -55.18% | -12.34 | 1.04 | -4.68% | -3204.17% |
EYPT | 80.8M | 42.4M | -41.42% | -80.17% | -1.03 | 1.9 | 30.40% | -43.67% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 1.7% | 44,915 | 44,167 | 42,820 | 41,123 | 39,211 |
S&GA Expenses | 0.2% | 8,993 | 8,972 | 8,768 | 8,458 | 8,007 |
R&D Expenses | -0.1% | 1,471 | 1,472 | 1,472 | 1,450 | 1,406 |
Costs and Expenses | 4.1% | 36,522 | 35,097 | 33,182 | 31,323 | 29,183 |
EBITDA | 0.7% | 9,547 | 9,485 | 9,979 | 10,058 | - |
EBITDA Margin | -1.0% | 0.21* | 0.21* | 0.23* | 0.24* | - |
Earnings Before Taxes | -1.1% | 7,835 | 7,920 | 8,496 | 8,628 | 8,841 |
EBT Margin | -2.7% | 0.17* | 0.18* | 0.20* | 0.21* | - |
Interest Expenses | 17.5% | 726 | 618 | 573 | 547 | 536 |
Net Income | -1.2% | 6,960 | 7,045 | 7,450 | 7,611 | 7,728 |
Net Income Margin | -2.9% | 0.15* | 0.16* | 0.17* | 0.19* | - |
Free Cahsflow | 23.4% | 6,911 | 5,600 | 6,336 | 7,001 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 7.3% | 97,154 | 90,536 | 90,579 | 92,747 | 95,123 |
Current Assets | 30.7% | 25,229 | 19,299 | 18,100 | 18,776 | 20,113 |
Cash Equivalents | 192.0% | 8,524 | 2,919 | 1,888 | 2,752 | 4,477 |
Inventory | -1.5% | 5,634 | 5,722 | 5,668 | 5,483 | 5,051 |
Net PPE | 7.6% | 9,280 | 8,628 | 8,529 | 8,448 | 8,333 |
Goodwill | 1.7% | 41,196 | 40,488 | 41,066 | 41,721 | 41,924 |
Current Liabilities | 53.0% | 17,010 | 11,118 | 10,997 | 12,070 | 13,436 |
Long Term Debt | 2.7% | 28,909 | 28,150 | 29,250 | 31,389 | 32,333 |
Shareholder's Equity | 1.0% | 43,978 | 43,549 | 42,354 | 41,018 | 40,793 |
Retained Earnings | 3.6% | 41,910 | 40,452 | 39,074 | 37,528 | 35,431 |
Additional Paid-In Capital | 0.9% | 16,743 | 16,596 | 16,467 | 16,292 | 16,174 |
Shares Outstanding | 0% | 392 | 392 | 392 | - | - |
Minority Interest | -8.5% | 54.00 | 59.00 | 61.00 | 62.00 | 62.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 12.7% | 9,154 | 8,124 | 8,837 | 9,536 | 9,312 |
Share Based Compensation | -0.6% | 307 | 309 | 283 | 257 | 230 |
Cashflow From Investing | 89.4% | -2,159 | -20,326 | -20,397 | -20,604 | -21,932 |
Cashflow From Financing | -186.0% | -2,810 | 3,266 | 6,457 | 8,286 | 6,581 |
Dividend Payments | 3.2% | 455 | 441 | 425 | 411 | 395 |
Buy Backs | 50.0% | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 |
16.1%
0%
0%
Y-axis is the maximum loss one would have experienced if Thermo Fisher Scientific was unfortunately bought at previous high price.
21.9%
21.8%
21.1%
22.0%
FIve years rolling returns for Thermo Fisher Scientific.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -3.72 | 947,853 | 21,596,900 | 0.60% |
2023-03-10 | BAILLIE GIFFORD & CO | reduced | -4.55 | 24,690,800 | 703,173,000 | 0.73% |
2023-03-10 | MATHER GROUP, LLC. | added | 25.16 | 348,517 | 1,320,520 | 0.03% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -6.4 | 2,797,580 | 174,467,000 | 0.19% |
2023-03-08 | Capital Asset Advisory Services LLC | reduced | -4.91 | 103,386 | 2,105,390 | 0.17% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | unchanged | - | 144,395 | 1,827,400 | 0.29% |
2023-03-07 | Great Lakes Retirement, Inc. | new | - | 626,709 | 626,709 | 0.16% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -2.72 | 5,345,000 | 100,453,000 | 0.50% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | reduced | -0.11 | 2,201,530 | 28,235,500 | 1.75% |
2023-03-03 | Crumly & Associates Inc. | reduced | -1.34 | 46,034 | 691,034 | 0.26% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 8.30% | 32,534,676 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 7.9% | 30,790,122 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 7.89% | 31,103,788 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 7.9% | 30,982,611 | SC 13G | |
Feb 10, 2021 | vanguard group inc | 7.82% | 30,997,381 | SC 13G/A | |
Feb 01, 2021 | blackrock inc. | 7.4% | 29,504,221 | SC 13G/A | |
Feb 12, 2020 | vanguard group inc | 7.77% | 31,187,697 | SC 13G/A | |
Feb 06, 2020 | blackrock inc. | 7.0% | 28,202,856 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 360.84 -35.23% | 467.87 -16.02% | 662.22 18.87% | 962.67 72.80% | 1245.53 123.58% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 15, 2023 | 4 | Insider Trading | |
Mar 14, 2023 | 144 | Notice of Insider Sale Intent | |
Mar 13, 2023 | 144 | Notice of Insider Sale Intent | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-14 | CASPER MARC N | sold | -4,153,450 | 553 | -7,500 | chairman & ceo |
2023-03-13 | CASPER MARC N | sold | -4,083,690 | 544 | -7,500 | chairman & ceo |
2023-03-05 | Lagarde Michel | sold (taxes) | -73,286 | 559 | -131 | executive vice president & coo |
2023-03-05 | Pettiti Gianluca | sold (taxes) | -36,923 | 559 | -66.00 | executive vice president |
2023-02-28 | Williamson Stephen | sold (taxes) | -452,370 | 541 | -835 | sr. vp and cfo |
2023-02-28 | Pettiti Gianluca | sold (taxes) | -420,948 | 541 | -777 | executive vice president |
2023-02-28 | CASPER MARC N | sold (taxes) | -1,445,960 | 541 | -2,669 | chairman & ceo |
2023-02-28 | Boxer Michael A | sold (taxes) | -120,812 | 541 | -223 | svp and general counsel |
2023-02-28 | Holmes Joseph R. | sold (taxes) | -21,128 | 541 | -39.00 | vp & chief accounting officer |
2023-02-28 | Lagarde Michel | sold (taxes) | -552,053 | 541 | -1,019 | executive vice president & coo |
Consolidated Statement of Income - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues | |||
Revenues | $ 44,915 | $ 39,211 | $ 32,218 |
Costs and operating expenses: | |||
Selling, general and administrative expenses | 8,993 | 8,007 | 6,930 |
Research and development expenses | 1,471 | 1,406 | 1,181 |
Restructuring and other costs | 114 | 197 | 99 |
Total costs and operating expenses | 36,522 | 29,183 | 24,424 |
Operating income | 8,393 | 10,028 | 7,794 |
Interest income | 272 | 43 | 65 |
Interest expense | (726) | (536) | (553) |
Other income/(expense) | (104) | (694) | (76) |
Income before income taxes | 7,835 | 8,841 | 7,230 |
Provision for income taxes | (703) | (1,109) | (850) |
Equity in earnings/(losses) of unconsolidated entities | (172) | (4) | (3) |
Net income | 6,960 | 7,728 | 6,377 |
Less: net income attributable to noncontrolling interests and redeemable noncontrolling interest | 10 | 3 | 2 |
Net income attributable to Thermo Fisher Scientific Inc. | $ 6,950 | $ 7,725 | $ 6,375 |
Earnings per share attributable to Thermo Fisher Scientific Inc. | |||
Basic (in dollars per share) | $ 17.75 | $ 19.62 | $ 16.09 |
Diluted (in dollars per share) | $ 17.63 | $ 19.46 | $ 15.96 |
Weighted average shares | |||
Basic (in shares) | 392 | 394 | 396 |
Diluted (in shares) | 394 | 397 | 399 |
Product revenues | |||
Revenues | |||
Revenues | $ 28,548 | $ 30,361 | $ 25,306 |
Costs and operating expenses: | |||
Cost of revenues | 14,247 | 13,594 | 11,407 |
Service revenues | |||
Revenues | |||
Revenues | 16,367 | 8,850 | 6,912 |
Costs and operating expenses: | |||
Cost of revenues | $ 11,697 | $ 5,979 | $ 4,807 |
Consolidated Balance Sheet - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 8,524 | $ 4,477 |
Accounts receivable, less allowances of $189 and $150 | 8,115 | 7,977 |
Inventories | 5,634 | 5,051 |
Contract assets, net | 1,312 | 968 |
Other current assets | 1,644 | 1,640 |
Total current assets | 25,229 | 20,113 |
Property, plant and equipment, net | 9,280 | 8,333 |
Acquisition-related intangible assets, net | 17,442 | 20,113 |
Other assets | 4,007 | 4,640 |
Goodwill | 41,196 | 41,924 |
Total assets | 97,154 | 95,123 |
Current liabilities: | ||
Short-term obligations and current maturities of long-term obligations | 5,579 | 2,537 |
Accounts payable | 3,381 | 2,867 |
Accrued payroll and employee benefits | 2,095 | 2,427 |
Contract liabilities | 2,601 | 2,655 |
Other accrued expenses | 3,354 | 2,950 |
Total current liabilities | 17,010 | 13,436 |
Deferred income taxes | 2,849 | 3,837 |
Other long-term liabilities | 4,238 | 4,540 |
Long-term obligations | 28,909 | 32,333 |
Commitments and Contingencies | ||
Redeemable noncontrolling interest | 116 | 122 |
Thermo Fisher Scientific Inc. shareholders’ equity: | ||
Preferred stock, $100 par value, 50,000 shares authorized; none issued | ||
Common stock, $1 par value, 1,200,000,000 shares authorized; 440,668,112 and 439,154,741 shares issued | 441 | 439 |
Capital in excess of par value | 16,743 | 16,174 |
Retained earnings | 41,910 | 35,431 |
Treasury stock at cost, 50,157,275 and 44,720,112 shares | (12,017) | (8,922) |
Accumulated other comprehensive items | (3,099) | (2,329) |
Total Thermo Fisher Scientific Inc. shareholders’ equity | 43,978 | 40,793 |
Noncontrolling interests | 54 | 62 |
Total equity | 44,032 | 40,855 |
Total liabilities, redeemable noncontrolling interest and equity | $ 97,154 | $ 95,123 |